<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37373850</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>12</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4158</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm12124158</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The post-acute sequelae of SARS-CoV-2 (PASC) infection have caused a significant impact on our health system, but there is limited evidence of approved drugs focused on its prevention. Our objective was to identify risk factors that can determine the presence of PASC, with special attention to the treatment received in the acute phase, and to describe the profile of persistent symptoms in a multidisciplinary Post-Coronavirus Disease-19 (COVID-19) Unit.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This one-year prospective observational study included patients following an acute COVID-19 infection, irrespective of whether they required hospital admission. A standardized symptom questionnaire and blood sampling were performed at the first follow-up visit, and demographic and clinical electronic data were collected. We compared subjects with PASC with those who had fully recovered. Multivariate logistic regression was performed to identify factors associated with PASC in hospitalized patients, and Kaplan-Meier curves were used to assess duration of symptoms according to disease severity and treatments received in the acute phase.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">1966 patients were evaluated; 1081 had mild disease, 542 moderate and 343 severe; around one third of the subjects had PASC, and were more frequently female, with obesity, asthma, and eosinophilia during acute COVID-19 disease. Patients who received treatment with dexamethasone and remdesivir during the course of the acute illness showed a lower median duration of symptoms, compared with those who received none of these treatments.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment with dexamethasone and/or remdesivir may be useful to reduce the impact of PASC secondary to SARS-CoV-2 infection. In addition, we identified female gender, obesity, asthma, and disease severity as risk factors for having PASC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Badenes Bonet</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caguana V&#xe9;lez</LastName><ForeName>Oswaldo Antonio</ForeName><Initials>OA</Initials><Identifier Source="ORCID">0000-0002-5028-7439</Identifier><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duran Jord&#xe0;</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Assessoria Metodol&#xf2;gica i Bioestad&#xed;stica (AMIB), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Comas Serrano</LastName><ForeName>Merce</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1926-2740</Identifier><AffiliationInfo><Affiliation>Epidemiology and Evaluation Department, Hospital del Mar, REDISSEC, RICAPPS, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Posso Rivera</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Epidemiology and Evaluation Department, Hospital del Mar, REDISSEC, RICAPPS, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Admetll&#xf3;</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herranz Blasco</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuadrado Godia</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9147-875X</Identifier><AffiliationInfo><Affiliation>Neurology Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marco Navarro</LastName><ForeName>Ester</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-3412-0356</Identifier><AffiliationInfo><Affiliation>Physical Medicine and Rehabilitation Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin Ezquerra</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-5106-7526</Identifier><AffiliationInfo><Affiliation>Dermatology Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineiro Aguin</LastName><ForeName>Zenaida</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Otorrinolaringology Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cumpli Gargallo</LastName><ForeName>Maria Cinta</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0009-0006-4359-0866</Identifier><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez Garcia</LastName><ForeName>Jose Gregorio</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0003-4682-8535</Identifier><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balcells Vilarnau</LastName><ForeName>Eva</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Respiratorias, (CIBERES), Instituto de Salud Carlos III (ISCIII), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodriguez Chiaradia</LastName><ForeName>Diego</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-8566-4011</Identifier><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Respiratorias, (CIBERES), Instituto de Salud Carlos III (ISCIII), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castells</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Epidemiology and Evaluation Department, Hospital del Mar, REDISSEC, RICAPPS, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gea</LastName><ForeName>Joaquim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Respiratory Medicine Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Respiratorias, (CIBERES), Instituto de Salud Carlos III (ISCIII), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horcajada</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0001-9873-5459</Identifier><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Red de Enfermedades Respiratorias, (CIBERES), Instituto de Salud Carlos III (ISCIII), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villar-Garc&#xed;a</LastName><ForeName>Judit</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hospital del Mar Medical Research Institute (IMIM), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Department, Hospital del Mar, 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>MAR Post-COVID-19 Unit</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">corticosteroids</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of COVID-19 (PASC)</Keyword><Keyword MajorTopicYN="N">remdesivir</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37373850</ArticleId><ArticleId IdType="pmc">PMC10299438</ArticleId><ArticleId IdType="doi">10.3390/jcm12124158</ArticleId><ArticleId IdType="pii">jcm12124158</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061&#x2013;1069. doi: 10.1001/jama.2020.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges D., Ballouz T., Anagnostopoulos A., Aschmann H.E., Domenghino A., Fehr J.S., Puhan M.A. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS ONE. 2021;16:e0254523. doi: 10.1371/journal.pone.0254523.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0254523</ArticleId><ArticleId IdType="pmc">PMC8274847</ArticleId><ArticleId IdType="pubmed">34252157</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan D., Pareek M. Toward a Universal Definition of Post-COVID-19 Condition-How Do We Proceed? JAMA Netw. Open. 2023;6:e235779. doi: 10.1001/jamanetworkopen.2023.5779.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.5779</ArticleId><ArticleId IdType="pubmed">37017975</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nature reviews. Microbiology. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue J.K., Franko N.M., McCulloch D.J., McDonald D., Magedson A., Wolf C.R., Chu H.Y. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw. Open. 2021;4:e210830. doi: 10.1001/jamanetworkopen.2021.0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F., Gemelli Against COVID-19 Post-Acute Care Study Group Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia C., Zurbuchen Y., Taeschler P., Ballouz T., Menges D., Hasler S., Adamo S., Raeber M.E., B&#xe4;chli E., Rudiger A., et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat. Commun. 2022;13:446. doi: 10.1038/s41467-021-27797-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27797-1</ArticleId><ArticleId IdType="pmc">PMC8789854</ArticleId><ArticleId IdType="pubmed">35078982</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh I.M., Saddik B., AlSwaidan N., AlAnazi A., Ramakrishnan R.K., Alhazmi D., Aloufi A., AlSumait F., Berbari E., Halwani R. Prevalence and predictors of Post-Acute COVID-19 Syndrome (PACS) after hospital discharge: A cohort study with 4 months median follow-up. PLoS ONE. 2021;16:e0260568. doi: 10.1371/journal.pone.0260568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0260568</ArticleId><ArticleId IdType="pmc">PMC8651136</ArticleId><ArticleId IdType="pubmed">34874962</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Molnupiravir and risk of post-acute sequelae of COVID-19: Cohort study. BMJ. 2023;381:e074572. doi: 10.1136/bmj-2022-074572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074572</ArticleId><ArticleId IdType="pmc">PMC10126525</ArticleId><ArticleId IdType="pubmed">37161995</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Intern. Med. 2023;183:554&#x2013;564. doi: 10.1001/jamainternmed.2023.0743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., et al. Dexamethasone in Hospitalized Patients with COVID-19. N. Engl. J. Med. 2021;384:693&#x2013;704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637&#x2013;1645. doi: 10.1016/S0140-6736(21)00676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Sim&#xf3;n-Campos A., et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N. Engl. J. Med. 2022;386:1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibila O., Molina-Molina M., Valenzuela C., R&#xed;os-Cort&#xe9;s A., Arbillaga-Etxarri A., Torralba Garc&#xed;a Y., D&#xed;az-P&#xe9;rez D., Landete P., Mediano O., Tom&#xe1;s L&#xf3;pez L., et al. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Consensus for Post-COVID-19 Clinical Follow-Up. Open Respir. Arch. 2020;2:278&#x2013;283. doi: 10.1016/j.opresp.2020.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.opresp.2020.09.002</ArticleId><ArticleId IdType="pmc">PMC7550863</ArticleId><ArticleId IdType="pubmed">38620714</ArticleId></ArticleIdList></Reference><Reference><Citation>Arribas J.R., Carolina Garcia-Vidal C., Gal&#xe1;n Montemayor J.C., Pa&#xf1;o J.R., Rodr&#xed;guez Ba&#xf1;o J. Recomendaciones SEIMC Para El Manejo Cl&#xed;nico de Pacientes Con COVID-19. Sociedad Espa&#xf1;ola de Enfermedades Infecciosas y Microbiolog&#xed;a Cl&#xed;nica 2:1&#x2013;2. 2020.  [(accessed on 1 May 2023)].  Available online:  https://seimc.org/contenidos/documentoscientificos/recomendaciones/seimc-rc-2020-COVID19-manejoclinico.pdf.</Citation></Reference><Reference><Citation>Lamontagne F., Agarwal A., Rochwerg B., Siemieniuk R.A., Agoritsas T., Askie L., Lytvyn L., Leo Y.S., Macdonald H., Zeng L., et al. A living WHO guideline on drugs for COVID-19. BMJ. 2020;370:m3379. doi: 10.1136/bmj.m3379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3379</ArticleId><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J., Waterboer T., Hippchen T., Simon J., Kirchner M., Lim A., M&#xfc;ller B., Merle U. Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2022;74:1191&#x2013;1198. doi: 10.1093/cid/ciab611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Zheng B., Daines L., Sheikh A. Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. Pathogens. 2022;11:269. doi: 10.3390/pathogens11020269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuszewski M., Szarpak L., Rafique Z., Peacock F.W., Pruc M., Szwed P., Chirico F., Navolokina A., Ladny J.R., Denegri A. Prediction Value of KREBS Von Den Lungen-6 (KL-6) Biomarker in COVID-19 Patients: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022;11:6600. doi: 10.3390/jcm11216600.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11216600</ArticleId><ArticleId IdType="pmc">PMC9658915</ArticleId><ArticleId IdType="pubmed">36362828</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialek B., De Roquetaillade C., Pruc M., Navolokina A., Chirico F., Ladny J.R., Peacock F.W., Szarpak L. Systematic review with meta-analysis of mid-regional pro-adrenomedullin (MR-proadm) as a prognostic marker in COVID-19-hospitalized patients. Ann. Med. 2023;55:379&#x2013;387. doi: 10.1080/07853890.2022.2162116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2162116</ArticleId><ArticleId IdType="pmc">PMC9828692</ArticleId><ArticleId IdType="pubmed">36607317</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuszewski M., &#x141;adny J., Rafique Z., Peacock F., Pruc M., Gasecka A., Szwed P., Jankowski L., Chmielewski J., Panasiuk L., et al. Prediction value of soluble urokinase plasminogen activator receptor (suPAR) in COVID-19 patients&#x2014;A systematic review and meta-analysis. Ann. Agric. Environ. Med. AAEM. 2023;30:142&#x2013;147. doi: 10.26444/aaem/160084.</Citation><ArticleIdList><ArticleId IdType="doi">10.26444/aaem/160084</ArticleId><ArticleId IdType="pubmed">36999867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cimellaro A., Addesi D., Cavallo M., Spagnolo F., Suraci E., Cordaro R., Spinelli I., Passafaro F., Colosimo M., Pintaudi M., et al. Monoclonal Antibodies and Antivirals against SARS-CoV-2 Reduce the Risk of Long COVID: A Retrospective Propensity Score-Matched Case-Control Study. Biomedicines. 2022;10:3135. doi: 10.3390/biomedicines10123135.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10123135</ArticleId><ArticleId IdType="pmc">PMC9775930</ArticleId><ArticleId IdType="pubmed">36551891</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the Treatment of COVID-19&#x2014;Final Report. N. Engl. J. Med. 2020;383:1813&#x2013;1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH Therapeutic Management of Adults with COVID-19.  [(accessed on 1 December 2022)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalizedadults--therapeutic-management/</Citation></Reference><Reference><Citation>NICE  Guideline [NG191]. COVID-19 Rapid Guideline: Managing COVID-19.  [(accessed on 31 December 2022)].  Available online:  https://app.magicapp.org/#/guideline/L4Qb5n/section/ERYAXn.</Citation></Reference><Reference><Citation>Bartoletti M., Azap O., Barac A., Bussini L., Ergonul O., Krause R., Pa&#xf1;o-Pardo J.R., Power N.R., Sibani M., Szabo B.G., et al. ESCMID COVID-19 living guidelines: Drug treatment and clinical management. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2022;28:222&#x2013;238. doi: 10.1016/j.cmi.2021.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.007</ArticleId><ArticleId IdType="pmc">PMC8606314</ArticleId><ArticleId IdType="pubmed">34823008</ArticleId></ArticleIdList></Reference><Reference><Citation>IDSA  IDSA Guidelines on the Treatment and Management of Patients with COVID-19.  [(accessed on 31 December 2022)].  Available online:  https://www.idsociety.org/practice-guideline/covid-19-guideline-treatmentand-management/</Citation></Reference><Reference><Citation>Garcia-Vidal C., Puerta-Alcalde P., Mateu A., Cuesta-Chasco G., Meira F., Lopera C., Monzo P., Santos-Bravo M., Duenas G., Chumbita M., et al. Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19. Haematologica. 2022;107:1731&#x2013;1735. doi: 10.3324/haematol.2021.280407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2021.280407</ArticleId><ArticleId IdType="pmc">PMC9244835</ArticleId><ArticleId IdType="pubmed">35295080</ArticleId></ArticleIdList></Reference><Reference><Citation>Niknam Z., Jafari A., Golchin A., Danesh Pouya F., Nemati M., Rezaei-Tavirani M., Rasmi Y. Potential therapeutic options for COVID-19: An update on current evidence. Eur. J. Med. Res. 2022;27:6. doi: 10.1186/s40001-021-00626-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40001-021-00626-3</ArticleId><ArticleId IdType="pmc">PMC8755901</ArticleId><ArticleId IdType="pubmed">35027080</ArticleId></ArticleIdList></Reference><Reference><Citation>Toussirot E., Marotte H., Mulleman D., Cormier G., Coury F., Gaudin P., Dernis E., Bonnet C., Damade R., Grauer J.L., et al. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: A 12-month multicentre study. Arthritis Res. Ther. 2020;22:224. doi: 10.1186/s13075-020-02297-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-020-02297-7</ArticleId><ArticleId IdType="pmc">PMC7523335</ArticleId><ArticleId IdType="pubmed">32993784</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillero E., Alamdari N., Aversa Z., Gurav A., Hasselgren P.O. PPAR&#x3b2;/&#x3b4; regulates glucocorticoid- and sepsis-induced FOXO1 activation and muscle wasting. PLoS ONE. 2013;8:e59726. doi: 10.1371/journal.pone.0059726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0059726</ArticleId><ArticleId IdType="pmc">PMC3605288</ArticleId><ArticleId IdType="pubmed">23555761</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C., Annane D., Azevedo L.C.P., Berwanger O., et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis. JAMA. 2020;324:1330&#x2013;1341. doi: 10.1001/jama.2020.17023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Schakman O., Kalista S., Barb&#xe9; C., Loumaye A., Thissen J.P. Glucocorticoid-induced skeletal muscle atrophy. Int. J. Biochem. Cell Biol. 2013;45:2163&#x2013;2172. doi: 10.1016/j.biocel.2013.05.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2013.05.036</ArticleId><ArticleId IdType="pubmed">23806868</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasan L.K., Deadwiler B., Haratian A., Bolia I.K., Weber A.E., Petrigliano F.A. Effects of COVID-19 on the Musculoskeletal System: Clinician&#x2019;s Guide. Orthop. Res. Rev. 2021;13:141&#x2013;150. doi: 10.2147/ORR.S321884.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ORR.S321884</ArticleId><ArticleId IdType="pmc">PMC8464590</ArticleId><ArticleId IdType="pubmed">34584465</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio C., Collins L.F., Malani P. Long-term Health Consequences of COVID-19. JAMA. 2020;324:1723&#x2013;1724. doi: 10.1001/jama.2020.19719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19719</ArticleId><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Committee for the COMEBAC Study Group. Morin L., Savale L., Pham T., Colle R., Figueiredo S., Harrois A., Gasnier M., Lecoq A.L., Meyrignac O., et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021;325:1525&#x2013;1534. doi: 10.1001/jama.2021.3331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3331</ArticleId><ArticleId IdType="pmc">PMC7970386</ArticleId><ArticleId IdType="pubmed">33729425</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Li X., Gu X., Zhang H., Ren L., Guo L., Liu M., Wang Y., Cui D., Wang Y., et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: A longitudinal cohort study. Lancet Respir. Med. 2022;10:863&#x2013;876. doi: 10.1016/S2213-2600(22)00126-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00126-6</ArticleId><ArticleId IdType="pmc">PMC9094732</ArticleId><ArticleId IdType="pubmed">35568052</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Zhou H., Zhou Y., Wu X., Zhao Y., Lu Y., Tan W., Yuan M., Ding X., Zou J., et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. J. Infect. 2020;81:e95&#x2013;e97. doi: 10.1016/j.jinf.2020.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.04.008</ArticleId><ArticleId IdType="pmc">PMC7162771</ArticleId><ArticleId IdType="pubmed">32305490</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A.W., Shah A.S., Johnston J.C., Carlsten C., Ryerson C.J. Patient-reported outcome measures after COVID-19: A prospective cohort study. Eur. Respir. J. 2020;56:2003276. doi: 10.1183/13993003.03276-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03276-2020</ArticleId><ArticleId IdType="pmc">PMC7530908</ArticleId><ArticleId IdType="pubmed">33008936</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y.M., Shang Y.M., Song W.B., Li Q.Q., Xie H., Xu Q.F., Jia J.L., Li L.M., Mao H.L., Zhou X.M., et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. eClinicalMedicine. 2020;25:100463. doi: 10.1016/j.eclinm.2020.100463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100463</ArticleId><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsampasian V., Elghazaly H., Chattopadhyay R., Debski M., Naing TK P., Garg P., Clark A., Ntatsaki E., Vassiliou V.S. Risk Factors Associated With Post-COVID-19 Condition: A Systematic Review and Meta-analysis. JAMA Int. Med. 2023;183:e230750. doi: 10.1001/jamainternmed.2023.0750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pmc">PMC10037203</ArticleId><ArticleId IdType="pubmed">36951832</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie P., Shi X., Zhu B., Zhao W., Li X., Zou X., Liu G., Han X. COVID-19 vaccine uptake, reasons, and associated factors among older adults in Shenzhen, China. Hum. Vaccines Immunother. 2023;19:2196914. doi: 10.1080/21645515.2023.2196914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2196914</ArticleId><ArticleId IdType="pmc">PMC10142320</ArticleId><ArticleId IdType="pubmed">37096742</ArticleId></ArticleIdList></Reference><Reference><Citation>Koller A., Szebeni J. COVID-19 vaccines elicit effective IgG responses in an elderly thymus cancer patient with chemotherapy. Hum. Vaccines Immunother. 2023;19:2188035. doi: 10.1080/21645515.2023.2188035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2188035</ArticleId><ArticleId IdType="pmc">PMC10114996</ArticleId><ArticleId IdType="pubmed">37062957</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T., Kherabi Y., MacDonald C.J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: A narrative review. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2022;28:202&#x2013;221. doi: 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L., Yao Q., Gu X., Wang Q., Ren L., Wang Y., Hu P., Guo L., Liu M., Xu J., et al. 1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study. Lancet. 2021;398:747&#x2013;758. doi: 10.1016/S0140-6736(21)01755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Han X., Fan Y., Alwalid O., Li N., Jia X., Yuan M., Li Y., Cao Y., Gu J., Wu H., et al. Six-month Follow-up Chest CT Findings after Severe COVID-19 Pneumonia. Radiology. 2021;299:E177&#x2013;E186. doi: 10.1148/radiol.2021203153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2021203153</ArticleId><ArticleId IdType="pmc">PMC7841877</ArticleId><ArticleId IdType="pubmed">33497317</ArticleId></ArticleIdList></Reference><Reference><Citation>Akdis C.A., Arkwright P.D., Br&#xfc;ggen M.C., Busse W., Gadina M., Guttman-Yassky E., Kabashima K., Mitamura Y., Vian L., Wu J., et al. Type 2 immunity in the skin and lungs. Allergy. 2020;75:1582&#x2013;1605. doi: 10.1111/all.14318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14318</ArticleId><ArticleId IdType="pubmed">32319104</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurya R., Sebastian P., Namdeo M., Devender M., Gertler A. COVID-19 Severity in Obesity: Leptin and Inflammatory Cytokine Interplay in the Link Between High Morbidity and Mortality. Front. Immunol. 2021;12:649359. doi: 10.3389/fimmu.2021.649359.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.649359</ArticleId><ArticleId IdType="pmc">PMC8250137</ArticleId><ArticleId IdType="pubmed">34220807</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B., Liu Z., Tang L., Li L., Gan Q., Shi H., Jiao Q., Guan Y., Xie M., He X., et al. Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. Int. J. Med. Sci. 2021;18:29&#x2013;41. doi: 10.7150/ijms.49728.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.49728</ArticleId><ArticleId IdType="pmc">PMC7738960</ArticleId><ArticleId IdType="pubmed">33390771</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialek B., Pruc M., Smereka J., Jas R., Rahnama-Hezavah M., Denegri A., Szarpak A., Jaguszewski M.J., Peacock F.W., Szarpak L. Diagnostic value of lactate dehydrogenase in COVID-19: A systematic review and meta-analysis. Cardiol. J. 2022;29:751&#x2013;758. doi: 10.5603/CJ.a2022.0056.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/CJ.a2022.0056</ArticleId><ArticleId IdType="pmc">PMC9550334</ArticleId><ArticleId IdType="pubmed">35762075</ArticleId></ArticleIdList></Reference><Reference><Citation>Szarpak L., Ruetzler K., Safiejko K., Hampel M., Pruc M., Kanczuga-Koda L., Filipiak K.J., Jaguszewski M.J. Lactate dehydrogenase level as a COVID-19 severity marker. Am. J. Emerg. Med. 2021;45:638&#x2013;639. doi: 10.1016/j.ajem.2020.11.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.11.025</ArticleId><ArticleId IdType="pmc">PMC7666711</ArticleId><ArticleId IdType="pubmed">33246860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruetzler K., Szarpak &#x141;., &#x141;adny J.R., G&#x105;secka A., Gilis-Malinowska N., Pruc M., Smereka J., Nowak B., Filipiak K.J., Jaguszewski M.J. D-dimer levels predict COVID-19 severity and mortality. Kardiol. Pol. 2021;79:217&#x2013;218. doi: 10.33963/KP.15830.</Citation><ArticleIdList><ArticleId IdType="doi">10.33963/KP.15830</ArticleId><ArticleId IdType="pubmed">33635034</ArticleId></ArticleIdList></Reference><Reference><Citation>Teuwen L.A., Geldhof V., Pasut A., Carmeliet P. COVID-19: The vasculature unleashed. Nat. Rev. Immunol. 2020;20:389&#x2013;391. doi: 10.1038/s41577-020-0343-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0343-0</ArticleId><ArticleId IdType="pmc">PMC7240244</ArticleId><ArticleId IdType="pubmed">32439870</ArticleId></ArticleIdList></Reference><Reference><Citation>Anka A.U., Tahir M.I., Abubakar S.D., Alsabbagh M., Zian Z., Hamedifar H., Sabzevari A., Azizi G. Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management. Scand. J. Immunol. 2021;93:e12998. doi: 10.1111/sji.12998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12998</ArticleId><ArticleId IdType="pmc">PMC7744910</ArticleId><ArticleId IdType="pubmed">33190302</ArticleId></ArticleIdList></Reference><Reference><Citation>Roca E., Ventura L., Zattra C.M., Lombardi C. EOSINOPENIA: An early, effective and relevant COVID-19 biomarker? QJM Mon. J. Assoc. Physicians. 2021;114:68&#x2013;69. doi: 10.1093/qjmed/hcaa259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcaa259</ArticleId><ArticleId IdType="pmc">PMC7499754</ArticleId><ArticleId IdType="pubmed">32877511</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazzaniga M., Fumagalli L.A.M., D&#x2019;angelo L., Cerino M., Bonfanti G., Fumagalli R.M., Schiavo G., Lorini C., Lainu E., Terragni S., et al. Eosinopenia is a reliable marker of severe disease and unfavourable outcome in patients with COVID-19 pneumonia. Int. J. Clin. Pract. 2021;75:e14047. doi: 10.1111/ijcp.14047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14047</ArticleId><ArticleId IdType="pmc">PMC7995195</ArticleId><ArticleId IdType="pubmed">33497517</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourda M., Dzidic M., Hertwig L., Bergsten H., Palma Medina L.M., Sinha I., Kvedaraite E., Chen P., Muvva J.R., Gorin J.B., et al. High-dimensional profiling reveals phenotypic heterogeneity and disease-specific alterations of granulocytes in COVID-19. Proc. Natl. Acad. Sci. USA. 2021;118:e2109123118. doi: 10.1073/pnas.2109123118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2109123118</ArticleId><ArticleId IdType="pmc">PMC8501786</ArticleId><ArticleId IdType="pubmed">34548411</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenderman L., Siemers M.J., van Aalst C., Bongers S.H., Spijkerman R., Bindels B.J.J., Giustarini G., van Goor H.M.R., Kaasjager K.A.H., Vrisekoop N. The Systemic Immune Response in COVID-19 Is Associated with a Shift to Formyl-Peptide Unresponsive Eosinophils. Cells. 2021;10:1109. doi: 10.3390/cells10051109.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10051109</ArticleId><ArticleId IdType="pmc">PMC8147959</ArticleId><ArticleId IdType="pubmed">34062964</ArticleId></ArticleIdList></Reference><Reference><Citation>Diny N.L., Rose N.R., &#x10c;ih&#xe1;kov&#xe1; D. Eosinophils in Autoimmune Diseases. Front. Immunol. 2017;8:484. doi: 10.3389/fimmu.2017.00484.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00484</ArticleId><ArticleId IdType="pmc">PMC5406413</ArticleId><ArticleId IdType="pubmed">28496445</ArticleId></ArticleIdList></Reference><Reference><Citation>Karlsson A.C., Humbert M., Buggert M. The known unknowns of T cell immunity to COVID-19. Sci. Immunol. 2020;5:eabe8063. doi: 10.1126/sciimmunol.abe8063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe8063</ArticleId><ArticleId IdType="pubmed">33208380</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslam A., Prasad V. Comparability of Control and Comparison Groups in Studies Assessing Long COVID. Am. J. Med. 2023 doi: 10.1016/j.amjmed.2023.01.005. Epub ahead of print.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2023.01.005</ArticleId><ArticleId IdType="pmc">PMC9912142</ArticleId><ArticleId IdType="pubmed">36708796</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>